Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

Publication date: 1 October 2019Source: Cell Reports, Volume 29, Issue 1Author(s): Michael J. Lukey, Ahmad A. Cluntun, William P. Katt, Miao-chong J. Lin, Joseph E. Druso, Sekar Ramachandran, Jon W. Erickson, Henry H. Le, Zhihan-Emily Wang, Bryant Blank, Kai Su Greene, Richard A. CerioneSummaryEfforts to target glutamine metabolism for cancer therapy have focused on the glutaminase isozyme GLS. The importance of the other isozyme, GLS2, in cancer has remained unclear, and it has been described as a tumor suppressor in some contexts. Here, we report that GLS2 is upregulated and essential in luminal-subtype breast tumors, which account for>70% of breast cancer incidence. We show that GLS2 expression is elevated by GATA3 in luminal-subtype cells but suppressed by promoter methylation in basal-subtype cells. Although luminal breast cancers resist GLS-selective inhibitors, we find that they can be targeted with a dual-GLS/GLS2 inhibitor. These results establish a critical role for GLS2 in mammary tumorigenesis and advance our understanding of how to target glutamine metabolism in cancer.Graphical Abstract
Source: Cell Reports - Category: Cytology Source Type: research